Before Invest
AMGEN INC logo

AMGEN INC

AMGN
Biological Products No Disgnostic Substances
Last filing · Quarter 2 · Jun 30, 2026
Financial Statements Ratios
Export XLSX
Statement
Income StatementBalance Sheet
Period
Annual Quarterly
Order
Unlock 14 years
Format
% Change
Rows
USD ($)
$ in Millions, shares in Millions		Dec 31, 2025Dec 31, 2024Dec 31, 2023Dec 31, 2022Dec 31, 2021Dec 31, 2020Dec 31, 2019Dec 31, 2018Dec 31, 2017Dec 31, 2016Dec 31, 2015Dec 31, 2014Dec 31, 2013Dec 31, 2012Dec 31, 2011Dec 31, 2010Dec 31, 2009
Current assets:
                 
Cash and cash equivalents
$ 9,129
$ 11,973
$ 10,944
Marketable securities
-
-
0
Trade receivables, net
9,570
6,782
7,268
Inventories
6,225
6,998
9,518
Other current assets
4,133
3,277
2,602
Total current assets
29,057
29,030
30,332
Property, plant and equipment, net
7,913
6,543
5,941
Intangible assets, net
22,276
27,699
32,641
Goodwill
18,680
18,637
18,629
Restricted investments
-
-
-
Other noncurrent assets
12,660
9,930
9,611
Total assets
90,586
91,839
97,154
LIABILITIES AND STOCKHOLDERS’ EQUITY
                 
Current liabilities:
                 
Accounts payable
2,367
1,908
1,590
Accrued liabilities
18,523
17,641
15,359
Current portion of long-term debt
4,599
3,550
1,443
Current portion of convertible notes
-
-
-
Total current liabilities
25,489
23,099
18,392
Long-term debt
50,005
56,549
63,170
Long-term deferred tax liabilities
1,366
1,616
2,354
Long-term tax liabilities
2,690
2,349
4,680
Convertible notes
-
-
-
Other noncurrent liabilities
2,378
2,349
2,326
Common Stock, Shares Authorized
-
-
-
Common Stock, Shares, Outstanding
-
-
-
Common Stock, Par or Stated Value Per Share
-
-
-
Stockholders’ equity:
                 
Common stock and additional paid-in capital; $0.0001 par value per share; 2,750.0 shares authorized; outstanding—538.8 shares in 2025 and 536.9 shares in 2024
34,023
33,533
33,070
Accumulated deficit
(25,107)
(27,590)
(26,549)
Accumulated other comprehensive loss
(258)
(66)
(289)
Total stockholders’ equity
8,658
5,877
6,232
Total liabilities and stockholders’ equity
$ 90,586
$ 91,839
$ 97,154